|
|
Prepublished online as a Blood First Edition Paper on February 27, 2003; DOI 10.1182/blood-2002-12-3842.
 Previous Article | Table of Contents | Next Article 
Blood, 1 July 2003, Vol. 102, No. 1, pp. 53-59
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation
Karoline Spaepen,
Sigrid Stroobants,
Patrick Dupont,
Peter Vandenberghe,
Johan Maertens,
Guy Bormans,
José Thomas,
Jan Balzarini,
Christine De Wolf-Peeters,
Luc Mortelmans, and
Gregor Verhoef
From the Departments of Nuclear Medicine, Oncology, Hematology, and Pathology, UZ Gasthuisberg, Leuven, Belgium; and Rega Institute, Katholieke Universiteit, Leuven, Belgium.
The study assessed the prognostic value of fluorine 18-fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) after salvage chemotherapy before high-dose chemotherapy with stem cell transplantation (HDT/SCT) in patients with induction failure or relapsing chemosensitive lymphoma. Retrospective analysis of the clinical and conventional imaging data of 60 patients scheduled for HDT/SCT was performed in parallel with the analysis of the [18F]FDG-PET results. To determine the ability of [18F]FDG-PET to predict clinical outcome, PET images were reread without knowledge of conventional imaging and clinical history. Presence or absence of abnormal [18F]FDG uptake was related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier survival analysis. Thirty patients showed a negative [18F]FDG-PET scan before HDT/SCT; 25 of those remained in complete remission, with a median follow-up of 1510 days. Two patients died due to a treatment-related mortality but without evidence of recurrent disease at that time (228-462 days). Only 3 patients had a relapse (median PFS, 1083 days) after a negative [18F]FDG-PET scan. Persistent abnormal [18F]FDG uptake was seen in 30 patients and 26 progressed (median PFS, 402 days); of these 26, 16 died from progressive disease (median OS, 408 days). Four patients are still in complete remission after a positive scan. Comparison between groups indicated a statistically significant association between [18F]FDG-PET findings and PFS (P < .000001) and OS (P < .00002). [18F]FDG-PET has an important prognostic role in the pretransplantation evaluation of patients with lymphoma and enlarges the concept of chemosensitivity used to select patients for HDT/SCT. (Blood. 2003;102:53-59)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Positron emission tomography predicts transplantation outcome
- David James Inwards
Blood 2003 102: 2.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. Soudack, R. B. Shalom, O. Israel, Y. Ben-Arie, Z. Levy, and D. Gaitini
Utility of Sonographically Guided Biopsy in Metabolically Suspected Recurrent Lymphoma
J. Ultrasound Med.,
February 1, 2008;
27(2):
225 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya
Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment
Jpn. J. Clin. Oncol.,
January 1, 2008;
38(1):
43 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Seam, M. E. Juweid, and B. D. Cheson
The role of FDG-PET scans in patients with lymphoma
Blood,
November 15, 2007;
110(10):
3507 - 3516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Toma, C. Granata, A. Rossi, and A. Garaventa
Multimodality Imaging of Hodgkin Disease and Non-Hodgkin Lymphomas in Children
RadioGraphics,
September 1, 2007;
27(5):
1335 - 1354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Juweid, S. Stroobants, O. S. Hoekstra, F. M. Mottaghy, M. Dietlein, A. Guermazi, G. A. Wiseman, L. Kostakoglu, K. Scheidhauer, A. Buck, et al.
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
J. Clin. Oncol.,
February 10, 2007;
25(5):
571 - 578.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al.
Revised Response Criteria for Malignant Lymphoma
J. Clin. Oncol.,
February 10, 2007;
25(5):
579 - 586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. W. Schot, J. M. Zijlstra, W. J. Sluiter, G. W. van Imhoff, J. Pruim, W. Vaalburg, and E. Vellenga
Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma
Blood,
January 15, 2007;
109(2):
486 - 491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Venugopal and S. A. Gregory
Lymphoproliferative disorders
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
265 - 297.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. L. Kasamon, R. J. Jones, and R. L. Wahl
Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma
J. Nucl. Med.,
January 1, 2007;
48(1_suppl):
19S - 27S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Cachin, H. M. Prince, A. Hogg, R. E. Ware, and R. J. Hicks
Powerful Prognostic Stratification By [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy
J. Clin. Oncol.,
July 1, 2006;
24(19):
3026 - 3031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Kalff, C. Duong, E. G. Drummond, J. P. Matthews, and R. J. Hicks
Findings on 18F-FDG PET Scans After Neoadjuvant Chemoradiation Provides Prognostic Stratification in Patients with Locally Advanced Rectal Carcinoma Subsequently Treated by Radical Surgery
J. Nucl. Med.,
January 1, 2006;
47(1):
14 - 22.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W A Weber
PET for response assessment in oncology: radiotherapy and chemotherapy
Br. J. Radiol.,
November 1, 2005;
Supplement_28(1):
42 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. A. Weber
Use of PET for Monitoring Cancer Therapy and for Predicting Outcome
J. Nucl. Med.,
June 1, 2005;
46(6):
983 - 995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res.,
April 15, 2005;
11(8):
2785 - 2808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Kazama, S. C. Faria, V. Varavithya, S. Phongkitkarun, H. Ito, and H. A. Macapinlac
FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls
RadioGraphics,
January 1, 2005;
25(1):
191 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Munker, J. Glass, L. K. Griffeth, T. Sattar, R. Zamani, M. Heldmann, R. Shi, and D. L. Lilien
Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease
Ann. Onc.,
November 1, 2004;
15(11):
1699 - 1704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Meyer, R. F. Ambinder, and S. Stroobants
Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice
Hematology,
January 1, 2004;
2004(1):
184 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Friedberg and V. Chengazi
PET Scans in the Staging of Lymphoma: Current Status
Oncologist,
October 1, 2003;
8(5):
438 - 447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
